Exicure Inc
XCUR
Company Profile
Business description
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Contact
2430 N. Halsted Street
Suite 410
ChicagoIL60614
USAT: +1 847 673-1700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
stocks
16 ASX stocks to buy and hold forever, revisited
This time last year, I highlighted 16 ASX stocks that investors could own indefinitely. One year on, I look at whether there should be any changes to the list of stocks as well as which companies are worth buying now.
stocks
This ASX200 reject could be a contrarian buying opportunity
Johns Lyng’s interim results and index deletion have sent investors running for the exits. Our analyst Esther Holloway thinks the sell-off is overdone.
stocks
A 15 step checklist from Buffett's forgotten inspiration
Phil Fisher achieved remarkable stock market returns by holding high quality growth companies for long periods of time. Here's how he found them.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,002.60 | 100.80 | -1.24% |
| CAC 40 | 7,988.96 | 47.05 | 0.59% |
| DAX 40 | 22,676.41 | 347.64 | 1.56% |
| Dow JONES (US) | 41,449.01 | 15.53 | 0.04% |
| FTSE 100 | 8,540.97 | 44.98 | 0.53% |
| HKSE | 23,600.31 | 181.83 | -0.76% |
| NASDAQ | 17,657.20 | 221.11 | 1.27% |
| Nikkei 225 | 36,819.09 | 25.98 | 0.07% |
| NZX 50 Index | 12,249.55 | 161.42 | -1.30% |
| S&P 500 | 5,609.61 | 37.54 | 0.67% |
| S&P/ASX 200 | 7,786.20 | 103.90 | -1.32% |
| SSE Composite Index | 3,371.92 | 7.90 | -0.23% |